VVOS Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (VVOS) is expected to report earnings on November 13, 2026, after the market close. The consensus earnings estimate is a loss of $0.36 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +11.7% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Vivos Therapeutics, Inc.
Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA).
Sector
Healthcare
Industry
Medical Appliances/Equipment